NovaBridge Biosciences (NBP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NBP Profit Margin, ROE & Profitability Analysis
NBP vs Healthcare Sector: How NovaBridge Biosciences Compares
How NovaBridge Biosciences compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NovaBridge Biosciences Stock Overvalued? NBP Valuation Analysis 2026
Based on fundamental analysis, NovaBridge Biosciences has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NovaBridge Biosciences Balance Sheet: NBP Debt, Cash & Liquidity
NBP Revenue Growth, EPS Growth & YoY Performance
NBP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NovaBridge Biosciences (CIK: 0001778016)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jul 10, 2026 | 4 | xslF345X06/form4-07102026_050705.xml | View → |
| Jul 10, 2026 | 4 | xslF345X06/form4-07102026_050707.xml | View → |
| Jul 8, 2026 | 4 | xslF345X06/form4-07082026_080720.xml | View → |
| Jul 7, 2026 | 4 | xslF345X06/form4-07072026_110715.xml | View → |
| Jun 30, 2026 | 4 | xslF345X06/form4-06302026_040618.xml | View → |
❓ Frequently Asked Questions about NBP
What is the AI rating for NBP?
NovaBridge Biosciences (NBP) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NBP's key strengths?
Claude: Analysis in progress.
What are the risks of investing in NBP?
Claude: Analysis in progress.
What is NBP's revenue and growth?
NovaBridge Biosciences reported revenue of N/A.
Does NBP pay dividends?
NovaBridge Biosciences does not currently pay dividends.
Where can I find NBP SEC filings?
Official SEC filings for NovaBridge Biosciences (CIK: 0001778016) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NBP's EPS?
NovaBridge Biosciences has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NBP's fundamental grade?
Based on our AI fundamental analysis in July 2026, NovaBridge Biosciences has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NBP stock overvalued or undervalued?
Valuation metrics for NBP: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NBP's AI grade for 2026?
Our dual AI analysis gives NovaBridge Biosciences a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NBP's free cash flow?
NovaBridge Biosciences's operating cash flow is N/A, with capital expenditures of N/A.
How does NBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).